Adicet Bio swaps shares for pre-funded warrant
Adicet Bio, Inc. entered into an exchange agreement with RA Capital under which RA Capital swapped 250,000 shares of Adicet common stock for a pre-funded warrant to acquire 250,000 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Adicet Bio, Inc. entered into an exchange agreement with RA Capital under which RA Capital swapped 250,000 shares of Adicet common stock for a pre-funded warrant to acquire 250,000 common shares.
The warrant carries a token exercise price of $0.0001 per share and is exercisable immediately via cashless exercise. It includes a 9.99% cap on both beneficial ownership and voting power, which can be increased on at least 61 days’ prior notice but not above 19.99%. The issuance relied on the Section 3(a)(9) exemption from Securities Act registration.
8-K Event Classification
2 items: 3.02, 9.01
2 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares exchanged: 250,000 shares
Warrant underlying shares: 250,000 shares
Exercise price: $0.0001 per share
+3 more
6 metrics
Shares exchanged
250,000 shares
Common stock swapped by RA Capital for warrant
Warrant underlying shares
250,000 shares
Common shares issuable upon exercise of pre-funded warrant
Exercise price
$0.0001 per share
Pre-funded warrant exercise price
Beneficial ownership cap
9.99%
Maximum beneficial ownership and voting power upon exercise
Maximum increased cap
19.99%
Upper limit if cap is increased after notice
Notice period to increase cap
61 days
Minimum prior notice to raise ownership cap
Key Terms
Pre-Funded Warrant, cashless exercise, beneficially owned, Section 3(a)(9) of the Securities Act of 1933, +2 more
6 terms
Pre-Funded Warrant financial
"for a pre-funded warrant (the Pre-Funded Warrant) to acquire 250,000 shares"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
cashless exercise financial
"The Pre-Funded Warrant is exercisable from the date of issuance by means of a cashless exercise."
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
beneficially owned financial
"aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Section 3(a)(9) of the Securities Act of 1933 regulatory
"in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended."
Section 3(a)(9) of the Securities Act of 1933 is a limited registration exemption that lets holders swap one security for another issued by the same company—common in reorganizations, mergers, exchanges or bankruptcy—without the company having to register the transaction with the SEC. Think of it like trading in an old product for a new model from the same maker: investors care because it can speed restructuring, cut legal costs and paperwork, and affect when and how shares become tradable, which in turn influences liquidity and potential dilution.
emerging growth company regulatory
"Emerging growth company Item 3.02 Unregistered Sales of Equity Securities."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL Document)."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity transaction did Adicet Bio (ACET) disclose in this 8-K?
Adicet Bio disclosed an exchange with RA Capital, where 250,000 common shares were swapped for a pre-funded warrant to acquire 250,000 common shares. This adjusts RA Capital’s position from stock into a warrant on equivalent share terms.
What is the exercise price of Adicet Bio’s new pre-funded warrant?
The pre-funded warrant issued by Adicet Bio has an exercise price of $0.0001 per share. This very low price means the economic value is largely embedded in the warrant itself rather than paid at exercise, and exercise is permitted through cashless settlement.
What ownership limits apply to RA Capital’s pre-funded warrant in Adicet Bio (ACET)?
The warrant cannot be exercised if it would cause RA Capital’s beneficial ownership or voting power to exceed 9.99% of Adicet’s outstanding securities. That cap can be increased with at least 61 days’ notice, but not above a maximum of 19.99%.
Under what legal exemption was Adicet Bio’s pre-funded warrant issued?
Adicet Bio issued the pre-funded warrant in reliance on Section 3(a)(9) of the Securities Act of 1933. This exemption allows exchanges of securities with existing holders without registration when specific conditions are met, as in this stock-for-warrant transaction.
When does the Adicet Bio pre-funded warrant issued to RA Capital become exercisable?
The pre-funded warrant issued to RA Capital is exercisable from the date of issuance. It can be exercised on a cashless basis, subject to the 9.99% beneficial ownership and voting power caps, and the potential increase up to 19.99% with proper advance notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates